Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMGEL vs AKOVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Treatment of acne vulgaris (FDA-approved),Topical treatment of inflammatory acne (FDA-approved),Ophthalmic infections: prophylaxis of neonatal conjunctivitis (off-label),Treatment of bacterial infections of the skin (off-label)
Treatment of clinically important hypotension occurring in the setting of anesthesia
Topical application of a thin layer to affected area twice daily; oral administration not applicable.
5 mg intravenously once daily.
Terminal elimination half-life: 1.5–2.0 hours in adults with normal renal function, prolonged in renal impairment (up to 6–8 hours with GFR <30 m L/min).
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) isoenzyme; excreted mainly in bile and feces.
Hepatic metabolism via oxidative deamination and demethylation; primarily metabolized by CYP2D6; some metabolites are active.
Almost entirely renal (90-95% as unchanged drug via glomerular filtration and tubular secretion), with less than 5% fecal or biliary elimination.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
70–80%, primarily to albumin.
85% bound to albumin and alpha-1-acid glycoprotein.
0.9–1.1 L/kg; indicates extensive extravascular distribution.
Vd: 1.5-2.0 L/kg, indicating extensive tissue distribution.
Topical: systemic absorption minimal (approximately 1–5%); oral: 50–60% (first-pass metabolism); intravenous: 100%.
Oral: 75% (first-pass metabolism minimal).
No dosage adjustment required for topical use.
Not required as AKOVAZ is not renally excreted.
No dosage adjustment required for topical use.
No dose adjustment needed based on Child-Pugh classification.
Safety and efficacy in children <12 years not established; for children ≥12 years, apply thin layer topically twice daily.
0.1 mg/kg intravenously once daily, maximum 5 mg.
No specific dose adjustment; use caution due to potential skin atrophy in elderly.
No specific dose adjustment required; use caution due to potential age-related decreased renal function.
No FDA black box warning for topical erythromycin.
None
May cause irritation, burning, stinging, or dryness at application site,Use with caution in patients with known hypersensitivity to erythromycin or any macrolide antibiotic,Superinfection may occur with prolonged use,Potential for bacterial resistance with prolonged use
Hypertension: May cause severe hypertension, including hypertensive crisis, especially with concurrent MAOIs or other vasopressors.,Arrhythmias: May induce ventricular arrhythmias, especially in patients with underlying cardiac disease.,Risk of stroke: Hypertensive effects may increase risk of intracranial hemorrhage.,Tachyphylaxis: Repeated use may lead to decreased response.,Extravasation: Risk of tissue necrosis if extravasation occurs.,Use caution in patients with hyperthyroidism, pheochromocytoma, or diabetes.
Hypersensitivity to erythromycin or any component of the formulation,Not for use in patients with known hepatic impairment (relative contraindication for systemic use, but topical use is generally safe)
Hypersensitivity to ephedrine or other sympathomimetics,Concurrent use with MAOIs or within 14 days after discontinuation,Angle-closure glaucoma,Severe hypertension or cardiovascular disease
No known food interactions. Avoid alcohol as it may increase risk of gastrointestinal irritation if oral salicylates are also used.
No known food interactions. This drug is administered intravenously, so dietary restrictions are not applicable. However, oral intake should not interfere with therapy.
EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and teeth, causing permanent discoloration and enamel hypoplasia; also associated with impaired skeletal growth and reversible inhibition of bone growth. First-trimester exposure is not associated with major malformations but may affect early bone and tooth development. Use contraindicated after first trimester.
Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. In second and third trimesters, use may cause fetal tachycardia, reduced uteroplacental blood flow, and potential for neonatal withdrawal or toxicity. Risk of maternal hypertension and decreased uterine perfusion outweighs benefits unless clearly indicated.
Tetracyclines are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.8). Theoretical risk of dental staining and bone growth inhibition in nursing infants exists, but absorption of tetracyclines from milk is limited due to chelation with calcium. Caution is advised; alternative therapies preferred.
Ephedrine is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.5-3.0. Peak milk concentration occurs 1-2 hours after dose. Potential for infant stimulation, irritability, and sleep disturbances. Use with caution; monitor infant for adverse effects. Avoid in lactation if possible or use lowest effective dose for shortest duration.
No dose adjustment required for EMGEL in pregnancy; however, tetracyclines are contraindicated after first trimester. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, decreased plasma protein binding) but no specific dose adjustment recommended due to contraindication. Use only when no alternative and clearly needed.
Pharmacokinetic changes in pregnancy (increased plasma volume, altered binding proteins) may reduce peak concentrations of ephedrine. However, no specific dose adjustment recommendations are established for Akovaz in pregnancy. Use the lowest effective dose to achieve desired effect (typically 5-10 mg IV for hypotension). Monitor clinical response closely; dose titration may be needed due to altered sensitivity of adrenergic receptors in pregnancy. Avoid prolonged use.
Apply sparingly to affected area; avoid contact with eyes, mucous membranes, and open wounds. Monitor for systemic absorption if used on large body surface areas. Use caution in patients with renal impairment due to potential for salicylate toxicity. Do not use with other topical preparations containing methyl salicylate.
AKOVAZ (ceftolozane/tazobactam) is a cephalosporin/beta-lactamase inhibitor combination used primarily for hospital-acquired pneumonia and complicated urinary tract infections. Monitor renal function closely; dose adjustment required for Cr Cl < 50 m L/min. Administer intravenously over 1 hour. Observe for hypersensitivity reactions, including anaphylaxis, particularly in penicillin-allergic patients. Consider cross-reactivity with other beta-lactams. Collect cultures before initiation.
Wash hands before and after application.,Apply only to intact skin, not on wounds or damaged skin.,Do not use with heating pads or bandages unless directed by doctor.,Avoid sun exposure to treated area as it may cause photosensitivity.,Discontinue if rash or irritation occurs and consult doctor.
This medication is given intravenously to treat serious bacterial infections.,Report any signs of allergic reaction immediately: rash, itching, difficulty breathing, swelling of face or throat.,Diarrhea may occur; contact your provider if it is severe, watery, or bloody.,Do not skip doses; complete the full course of treatment even if you feel better.,Tell your healthcare provider about all medications, especially blood thinners (e.g., warfarin) and other antibiotics.,Kidney function will be monitored with blood tests; drink adequate fluids unless told otherwise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMGEL vs AKOVAZ, answered by our medical review team.
EMGEL is a Topical Antibiotic that works by Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It also has anti-inflammatory and immunomodulatory effects, including inhibition of neutrophil chemotaxis and modulation of cytokine production.. AKOVAZ is a Topical Antibiotic that works by Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMGEL and AKOVAZ depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMGEL is: Topical application of a thin layer to affected area twice daily; oral administration not applicable.. The standard adult dose of AKOVAZ is: 5 mg intravenously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMGEL and AKOVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMGEL is classified as Category C. EMGEL contains tetracycline-class antibiotic. Tetracyclines are associated with fetal risk primarily in second and third trimesters due to incorporation into developing bone and te. AKOVAZ is classified as Category C. Akovaz (ephedrine sulfate) is classified as FDA Pregnancy Category C. In first trimester, there is insufficient human data; animal studies show teratogenic effects at high doses. I. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.